Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thalidomide
Drug ID BADD_D02192
Description A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Indications and Usage For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Marketing Status Prescription
ATC Code L04AX02
DrugBank ID DB01041
KEGG ID D00754
MeSH ID D013792
PubChem ID 5426
TTD Drug ID D0U7GK
NDC Product Code 59572-205; 59572-210; 59572-220; 59572-215; 69988-0052; 63818-0424; 17337-0301; 68554-0011
Synonyms Thalidomide | Sedoval | Thalomid
Chemical Information
Molecular Formula C13H10N2O4
CAS Registry Number 50-35-1
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Deep vein thrombosisThrombomodulinP07204T0858315235749; 7878634
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.008685%
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Acne23.02.01.0010.002895%Not Available
Acquired immunodeficiency syndrome11.05.17.007; 10.03.03.001--Not Available
Acute leukaemia16.01.02.001; 01.10.02.001--Not Available
Acute lymphocytic leukaemia16.01.01.001; 01.10.01.0010.000604%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.001208%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.001--Not Available
Acute respiratory distress syndrome22.01.03.0010.000604%
Ageusia17.02.07.001; 07.14.03.0030.002895%Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.001--Not Available
Amblyopia06.02.01.001--Not Available
Amenorrhoea21.01.02.001; 05.05.01.002--
Ammonia increased13.03.01.0230.001158%Not Available
Amnesia17.03.02.001; 19.20.01.001--
Amyloidosis10.02.05.0010.000755%Not Available
Anaemia01.03.02.0010.020265%
Anaemia macrocytic14.12.01.002; 01.03.02.002--Not Available
Anaemia megaloblastic14.12.01.003; 01.03.02.003--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Ankle fracture12.04.01.005; 15.08.03.0050.001737%
The 1th Page    1 2 3 4 5    Next   Last    Total 24 Pages